Get Red Pepper's email newsletter. Enter your email address to receive our latest articles, updates and news.

×

Held hostage by Big Pharma: a personal experience

Mike Marqusee looks at how drug firms can make huge profits from their state-enforced monopoly on an essential good

November 26, 2013
7 min read


Mike MarquseeMike Marqusee 1953–2015, wrote a regular column for Red Pepper, 'Contending for the Living', and authored a number of books on the politics of culture, on topics ranging from cricket to Bob Dylan.


  share     tweet  

In recent months, I’ve been taking a medication called Revlimid, given as a ‘late therapy’ for multiple myeloma. Since it looks like I may be Revlimid-dependent for a while, I decided to educate myself about the drug. As the chemistry is beyond me, I focussed my attention elsewhere.

The first thing I discovered was that Revlimid is phenomenally expensive.

A single 21-day cycle of treatment at the lowest dose of 5 mg daily costs the NHS £3,570. As the dose rises, so does the price, but not proportionally: for a single 21 day cycle at the high dose of 25 mg, it’s £4,318. The increment is small because the costs of actually manufacturing the drug are minimal. But whatever it is that we’re paying for, we’re paying for it through the nose: between £42,000 and £51,000 per patient for a year’s treatment. This is a treatment we need and to which we have a right. That does not, however, mean that its cost should be taken for granted.

Revlimid, it turns out, is a major profit generator for a medium-sized pharmaceutical company called Celgene, based in New Jersey. Though it directly employs only 4,000 people, Celgene’s 2012 revenues were $6.2 billion, up from $5.5 billion the previous year. After paying tax (at an effective rate of only 5%), profits on that revenue amounted to $1.6 billion, a 26% profit-to-sales ratio, high even by pharma industry standards.

Sales of Revlimid contributed more than $1 billion to Celgene’s revenues last year, making it by some way the company’s biggest cash cow. The Revlimid patent extends to 2027 and according to the company, ‘revenue is not near its potential peak’. (The drug has recently been approved for use in China.) Not surprisingly, Celgene’s NASDAQ listed share price has risen steadily, up 113% over the last year.

Celgene also makes the version of thalidomide used in the treatment of multiple myeloma as well as a new myeloma therapy called Pomalyst, licensed in the USA and currently under review by NICE.

Who knew so much money could be made out of multiple myeloma? It’s considered a rare disease, accounting for only one per cent of all cancers. Currently there are about 14,000 people in Britain and 75,000 in the USA living with multiple myeloma. Not a vast market but clearly a profitable one, though still only a sliver of the $1.1 trillion global pharmaceutical industry.

Like other pharmaceutical companies, Celgene claims its high prices are needed to sustain research and development. However, like other pharmaceutical companies, Celgene spends the majority of its revenue not on R&D, but on sales, marketing, lobbying, legal fees, acquisitions, plus the 26% dispersed in profits. In keeping with an industry-wide trend, revenues and profits have grown faster than investment in R&D.

Exclusive license

Celgene can charge exorbitantly for Revlimid because it owns an exclusive license to produce it. The formula itself is easy to replicate and if it were not for legal restraints, could be produced generically for a fraction of the cost. This multi-billion dollar business is built on a state-enforced monopoly of an essential good.

On examination, the rationale for that monopoly crumbles. Scientific research is cumulative and collective. The development of Revlimid was only possible because of a chain of advances in molecular biology and other disciplines. On what basis does the fruit of that process belong exclusively to Celgene’s shareholders?

In a revealing trend, pharmaceutical companies increasingly out-source core functions, including drug discovery itself. This reduces fixed costs but vitiates the neoliberal argument that innovation is inextricably tied to private ownership of the final product. It shows that innovation can be paid for and rewarded as a separate function, and that patent-holding exclusivity is not a necessary component of the process.

According to Big Pharma, their corporate model is the only way to advance research. Historically, however, medical advances have largely depended on public institutions (hospitals and universities); the corporate model is relatively recent. It is also a model compromised at its scientific core. The reliance on capitalist incentive for investment, as opposed to investment determined by public need, distorts the field as a whole. Increasingly, research is dictated by marketing. The aim is to produce a profitable drug; R&D priorities are set accordingly. As can be seen in the long-running resistance of Big Pharma to full publication of clinical trials data, the imperatives of competition put a brake on the sharing of information, which is the basis of scientific advance.

Patenting the sun

Jonas Salk, who discovered the first polio vaccine in the early 1950s, refused to take out a patent for the drug. Explaining his logic, he asked rhetorically, “Could you patent the sun?” He also noted that he had already been paid for his work on the drug through his regular salary as a university-based research scientist. (Not surprisingly, he was placed under surveillance by the FBI.)

Celgene has been criticised for its involvement in the American Legislative Exchange Council (ALEC), a body described by John Nichols in The Nation as a ‘collaboration between multinational corporations and conservative state legislators’. ALEC’s causes include reducing corporate regulation and taxation, privatising public services, tightening voter identification rules (making it harder for minorities, students and the poor to vote), minimizing environmental protection and promoting gun rights. It’s also zealous for ‘tougher’, longer sentencing, which directly benefits ALEC members like the Corrections Corporation of America and the GEO Group, two of the US’s largest for-profit prison companies.

ALEC also promotes ‘Stand-your-ground laws’ of the type used in Florida to justify the murder of Trayvon Martin. In response to that atrocity, activists announced a boycott of Coca-Cola because of its support for ALEC. Within hours, the company announced it was ending its relationship with the right-wing lobbying group. Others followed, including Wendy’s, Kraft Foods, McDonald’s, Apple, Procter & Gamble and even Wal-mart. But not Celgene, or indeeed GlaxoSmithKline, Bayer, Pfizer, or PhRMA (the pharmaceutical trade group). Alongside Big Pharma, tobacco, oil and energy giants also remain committed to ALEC.

Responding to criticisms of Celgene’s support for ALEC, Greg Chesmore, the company’s Senior Director of State Government Relations, declared last year that ‘participation in ALEC is consistent with Celgene’s vision, mission, values, and fully aligned with our commitment to improve the lives of patients worldwide’. In a perverse way, all that’s true.

In July 2012, The Guardian reported that ALEC had extended its operation to Britain, where it is lobbying against plain packaging of cigarettes. So it appears that some, admittedly small, part of the money the NHS hands over every year to Celgene ends up funding a campaign to undermine the health of people in Britain, adding to the NHS burden.

The NHS is spending a lot of money keeping me going. It was indeed the ‘cost-effectiveness’ of Revlimid that made NICE initially reluctant to approve it. After a vigorous public campaign by patient advocacy groups, NICE changed its position and Revlimid was made available on the NHS. I’m a beneficiary of this campaign, but so is Celgene. The clamour to save or prolong lives like mine undermined NICE’s bargaining position and strengthened Celgene’s. It’s a pattern seen in other controversies involving NICE, where health charities collaborate with pharmaceutical companies in pressing for rapid approval of new drugs.

Of course, the very idea of determining the “cost effectiveness” of a life-prolonging treatment is grotesque. What formula can possibly measure this kind of value? But anger at NICE is misdirected. The real problem is the extortionate prices demanded for life-prolonging drugs, and the real culprits are the pharmaceutical companies, who too often get away with making NICE the fall-guy for their rapacity.

In effect, companies like Celgene are hostage-takers: pay the ransom, they demand, or someone dies. The ruthlessness is breathtaking but is accepted as a corporate behavioural norm. What makes it more arch is that the hostage-taker claims to be on the side of the hostages. Though I’m one of those being held hostage by Big Pharma, I’ve experienced no trace of Stockholm Syndrome. On the contrary, I resent the way my illness, my vulnerability, has been exploited, used by a group of self-serving parasites to gouge the public purse.

www.mikemarqusee.com

Red Pepper is an independent, non-profit magazine that puts left politics and culture at the heart of its stories. We think publications should embrace the values of a movement that is unafraid to take a stand, radical yet not dogmatic, and focus on amplifying the voices of the people and activists that make up our movement. If you think so too, please support Red Pepper in continuing our work by becoming a subscriber today.
Why not try our new pay as you feel subscription? You decide how much to pay.
Share this article  
  share on facebook     share on twitter  

Mike MarquseeMike Marqusee 1953–2015, wrote a regular column for Red Pepper, 'Contending for the Living', and authored a number of books on the politics of culture, on topics ranging from cricket to Bob Dylan.


What is ‘free movement plus’?
A new report proposes an approach that can push back against the tide of anti-immigrant sentiment. Luke Cooper explains

The World Transformed: Red Pepper’s pick of the festival
Red Pepper is proud to be part of organising The World Transformed, in Brighton from 23-26 September. Here are our highlights from the programme

Working class theatre: Save Our Steel takes the stage
A new play inspired by Port Talbot’s ‘Save Our Steel’ campaign asks questions about the working class leaders of today. Adam Johannes talks to co-director Rhiannon White about the project, the people and the politics behind it

The dawn of commons politics
As supporters of the new 'commons politics' win office in a variety of European cities, Stacco Troncoso and Ann Marie Utratel chart where this movement came from – and where it may be going

A very social economist
Hilary Wainwright says the ideas of Robin Murray, who died in June, offer a practical alternative to neoliberalism

Art the Arms Fair: making art not war
Amy Corcoran on organising artistic resistance to the weapons dealers’ London showcase

Beware the automated landlord
Tenants of the automated landlord are effectively paying two rents: one in money, the other in information for data harvesting, writes Desiree Fields

Black Journalism Fund – Open Editorial Meeting
3-5pm Saturday 23rd September at The World Transformed in Brighton

Immigration detention: How the government is breaking its own rules
Detention is being used to punish ex-prisoners all over again, writes Annahita Moradi

A better way to regenerate a community
Gilbert Jassey describes a pioneering project that is bringing migrants and local people together to repopulate a village in rural Spain

Fast food workers stand up for themselves and #McStrike – we’re loving it!
McDonald's workers are striking for the first time ever in Britain, reports Michael Calderbank

Two years of broken promises: how the UK has failed refugees
Stefan Schmid investigates the ways Syrian refugees have been treated since the media spotlight faded

West Papua’s silent genocide
The brutal occupation of West Papua is under-reported - but UK and US corporations are profiting from the violence, write Eliza Egret and Tom Anderson

Activate, the new ‘Tory Momentum’, is 100% astroturf
The Conservatives’ effort at a grassroots youth movement is embarrassingly inept, writes Samantha Stevens

Peer-to-peer production and the partner state
Michel Bauwens and Vasilis Kostakis argue that we need to move to a commons-centric society – with a state fit for the digital age

Imagining a future free of oppression
Writer, artist and organiser Ama Josephine Budge says holding on to our imagination of tomorrow helps create a different understanding today

The ‘alt-right’ is an unstable coalition – with one thing holding it together
Mike Isaacson argues that efforts to define the alt-right are in danger of missing its central component: eugenics

Fighting for Peace: the battles that inspired generations of anti-war campaigners
Now the threat of nuclear war looms nearer again, we share the experience of eighty-year-old activist Ernest Rodker, whose work is displayed at The Imperial War Museum. With Jane Shallice and Jenny Nelson he discussed a recent history of the anti-war movement.

Put public purpose at the heart of government
Victoria Chick stresses the need to restore the public good to economic decision-making

Don’t let the world’s biggest arms fair turn 20
Eliza Egret talks to activists involved in almost two decades of protest against London’s DSEI arms show

The new municipalism is part of a proud radical history
Molly Conisbee reflects on the history of citizens taking collective control of local services

With the rise of Corbyn, is there still a place for the Green Party?
Former Green principal speaker Derek Wall says the party may struggle in the battle for votes, but can still be important in the battle of ideas

Fearless Cities: the new urban movements
A wave of new municipalist movements has been experimenting with how to take – and transform – power in cities large and small. Bertie Russell and Oscar Reyes report on the growing success of radical urban politics around the world

A musical fightback against school arts cuts
Elliot Clay on why his new musical turns the spotlight on the damage austerity has done to arts education, through the story of one school band's battle

Neoliberalism: the break-up tour
Sarah Woods and Andrew Simms ask why, given the trail of destruction it has left, we are still dancing to the neoliberal tune

Cat Smith MP: ‘Jeremy Corbyn has authenticity. You can’t fake that’
Cat Smith, shadow minister for voter engagement and youth affairs and one of the original parliamentary backers of Corbyn’s leadership, speaks to Ashish Ghadiali

To stop the BBC interviewing climate deniers, we need to make climate change less boring
To stop cranks like Lord Lawson getting airtime, we need to provoke more interesting debates around climate change than whether it's real or not, writes Leo Barasi

Tory Glastonbury? Money can’t buy you cultural relevance
Adam Peggs on why the left has more fun

Essay: After neoliberalism, what next?
There are economically-viable, socially-desirable alternatives to the failed neoliberal economic model, writes Jayati Ghosh

With the new nuclear ban treaty, it’s time to scrap Trident – and spend the money on our NHS
As a doctor, I want to see money spent on healthcare not warfare, writes David McCoy - Britain should join the growing international movement for disarmament


20